- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- January 2025
- 205 Pages
Global
From €4767EUR$4,995USD£3,994GBP
- Report
- May 2022
- 38 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 88 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Clinical Trials
- January 2021
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- August 2021
- 155 Pages
Global
From €2386EUR$2,500USD£1,999GBP
Vulval Atrophy is a condition that affects women's health, characterized by thinning and inflammation of the vulval skin. It is caused by a decrease in estrogen levels, which can occur naturally during menopause or as a result of certain medical treatments. Symptoms of Vulval Atrophy include itching, burning, and pain during intercourse. Treatment options include topical creams, oral medications, and laser therapy.
The Vulval Atrophy market is an important part of Women's Health, as it provides treatments for a condition that can have a significant impact on quality of life. Companies in this market are focused on developing treatments that are effective, safe, and easy to use. Examples of companies in this market include Allergan, Pfizer, and Merck. Show Less Read more